Close Menu


FIND is granting an award to Altona Dx, Cepheid, and the Bernhard Nocht Institute to develop an assay for Lassa virus. It also signed an MOU with the UK government to combat antimicrobial resistance.

The study is the first to demonstrate the design features and operational characteristics of Cepheid's Xpert MTB/RIF Ultra assay.

The test will leverage Chembio's DPP technology platform to detect multiple diseases simultaneously. 

The IGRA testing market is ballooning as industrialized nations try to curb the spread of tuberculosis, but the assays still fall short in certain settings and patient populations.

The company will work with the nonprofit to create a test for resource-poor settings. It is also working under a new NIH grant to add antibiotic susceptibility testing to its system.